Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karoline Bechtold-Peters

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Journal of Pharmaceutical Sciences|February 2, 2023
An Intra-Company Analysis of Inherent Particles in Biologicals Shapes the Protein Particle Mitigation Strategy Across Development StagesSorina Morar-Mitrica, Thomas Pohl, Dietmar Theisen, et al.
The AAPS Journal|November 3, 2019
Phase-Appropriate Application of Analytical Methods to Monitor Subvisible Particles Across the Biotherapeutic Drug Product Life CycleRoman Mathaes, Linda Narhi, Andrea Hawe, et al.
Lab on a Chip|August 4, 2025
Utility of an <i>in vitro</i> lymphatics on-chip model for rank ordering subcutaneous absorption of monoclonal antibodiesAdriana Martinez Ledo, Gabriela Misiewicz, Thomas Dimke, et al.
Journal of Pharmaceutical Sciences|March 24, 2010
An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeuticsSatish K Singh, Nataliya Afonina, Michel Awwad, et al.
Journal of Pharmaceutical Sciences|January 19, 2026
Do we worry too much about polysorbate degradation? An industry-wide perspective with real-life case studiesKlaus Wuchner, Felix Nikels, Patrick Garidel, et al.
Journal of Pharmaceutical Sciences|September 23, 2023
CMC Regulatory Considerations for Antibody-Drug ConjugatesKaroline Bechtold-Peters, Andrea Ruggiero, Nienke Vriezen, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|August 15, 2023
Compliance and regulatory considerations for the implementation of the multi-attribute-method by mass spectrometry in a quality control laboratoryAnnick Gervais, Eef H C Dirksen, Thomas Pohl, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|May 5, 2023
Technical considerations for the implementation of the multi-attribute-method by mass spectrometry in a quality control laboratoryThomas Pohl, Annick Gervais, Eef H C Dirksen, et al.
Journal of Pharmaceutical Sciences|August 24, 2022
Industry Perspective on the Use and Characterization of Polysorbates for Biopharmaceutical Products Part 2: Survey Report on Control Strategy Preparing for the FutureKlaus Wuchner, Linda Yi, Cyrille Chery, et al.
Journal of Pharmaceutical Sciences|February 22, 2022
Industry Perspective on the use and Characterization of Polysorbates for Biopharmaceutical Products Part 1: Survey Report on Current State and Common Practices for Handling and Control of PolysorbatesKlaus Wuchner, Linda Yi, Cyrille Chery, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Journal of Pharmaceutical Sciences|February 2, 2023
An Intra-Company Analysis of Inherent Particles in Biologicals Shapes the Protein Particle Mitigation Strategy Across Development StagesSorina Morar-Mitrica, Thomas Pohl, Dietmar Theisen, et al.
The AAPS Journal|November 3, 2019
Phase-Appropriate Application of Analytical Methods to Monitor Subvisible Particles Across the Biotherapeutic Drug Product Life CycleRoman Mathaes, Linda Narhi, Andrea Hawe, et al.
Lab on a Chip|August 4, 2025
Utility of an <i>in vitro</i> lymphatics on-chip model for rank ordering subcutaneous absorption of monoclonal antibodiesAdriana Martinez Ledo, Gabriela Misiewicz, Thomas Dimke, et al.
Journal of Pharmaceutical Sciences|March 24, 2010
An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeuticsSatish K Singh, Nataliya Afonina, Michel Awwad, et al.
Journal of Pharmaceutical Sciences|January 19, 2026
Do we worry too much about polysorbate degradation? An industry-wide perspective with real-life case studiesKlaus Wuchner, Felix Nikels, Patrick Garidel, et al.
Journal of Pharmaceutical Sciences|September 23, 2023
CMC Regulatory Considerations for Antibody-Drug ConjugatesKaroline Bechtold-Peters, Andrea Ruggiero, Nienke Vriezen, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|August 15, 2023
Compliance and regulatory considerations for the implementation of the multi-attribute-method by mass spectrometry in a quality control laboratoryAnnick Gervais, Eef H C Dirksen, Thomas Pohl, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|May 5, 2023
Technical considerations for the implementation of the multi-attribute-method by mass spectrometry in a quality control laboratoryThomas Pohl, Annick Gervais, Eef H C Dirksen, et al.
Journal of Pharmaceutical Sciences|August 24, 2022
Industry Perspective on the Use and Characterization of Polysorbates for Biopharmaceutical Products Part 2: Survey Report on Control Strategy Preparing for the FutureKlaus Wuchner, Linda Yi, Cyrille Chery, et al.
Journal of Pharmaceutical Sciences|February 22, 2022
Industry Perspective on the use and Characterization of Polysorbates for Biopharmaceutical Products Part 1: Survey Report on Current State and Common Practices for Handling and Control of PolysorbatesKlaus Wuchner, Linda Yi, Cyrille Chery, et al.
Pageof 4